Key result
Multiple pharmacotherapies show promise for stuttering priapism but lack high-level evidence for a universal strategy.
Why the study?
There is a paucity of peer-reviewed evidence to guide medical management of stuttering priapism and no universally adopted therapeutic strategy.
What are the current management options and pathophysiology of stuttering priapism?
What are the current management options and pathophysiology of stuttering priapism?
Stuttering priapism remains an under-investigated disorder without a universally adopted therapeutic strategy, highlighting the need for further research.
Answers are grounded in this paper and cite their sources.
No universal strategy for stuttering priapism; leaves open the need for RCTs to establish evidence-based protocols.
Purpose of Review There is a paucity of peer-reviewed evidence to guide medical management of stuttering priapism. The purpose of this review is to summarize the current understanding regarding the pathophysiology of priapism and management options for stuttering priapism. Recent Findings Conducting large-scale, randomized, placebo-controlled trials that elucidate the optimal treatment of stuttering priapism is challenging. Therefore, recent treatment guidelines are based upon small case series, retrospective studies, and expert opinions. Nonetheless, multiple compounds from various drug classes have shown promise in treating stuttering priapism, and a few pharmacotherapies such as Crizanlizumab are currently under active investigation. Summary Stuttering priapism is an under-investigated disorder with a complex pathophysiology. Currently, there is no wildly adopted universal therapeutic strategy. Further research is warranted to identify the appropriate treatment of stuttering priapism and to determine the long-term side effects of current pharmacotherapies.
No takes yet. Share an insight, caveat, or question.
Hammad et al. (2022) conducted a review in Stuttering priapism. Pharmacotherapies (e.g., PDE5 inhibitors, ketoconazole, sympathomimetics) was evaluated. Multiple pharmacotherapies show promise in treating stuttering priapism, but there is currently no widely adopted universal therapeutic strategy due to a lack of high-level evidence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: